Search Results - "Brown, Annie Kathleen"

CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results by Schultz, Liora M., Jeyakumar, Nikeshan, Kramer, Anne Marijn, Sahaf, Bita, Srinagesh, Hrishi, Shiraz, Parveen, Agarwal, Neha, Hamilton, Mark, Erickson, Courtney, Jacobs, Ashley, Moon, Jennifer, Baggott, Christina, Arai, Sally, Bharadwaj, Sushma, Johnston, Laura J., Liedtke, Michaela, Lowsky, Robert, Meyer, Everett, Negrin, Robert, Rezvani, Andrew, Shizuru, Judy, Sidana, Surbhi, Egeler, Emily, Mavroukakis, Sharon, Tunuguntla, Ramya, Gkitsas-Long, Nikolaos, Retherford, Aidan, Brown, Annie Kathleen, Gramstrap-Petersen, Anne-Louise, Ibañez, Raquel Martin, Feldman, Steven A., Miklos, David B., Mackall, Crystal L., Davis, Kara L., Frank, Matthew, Ramakrishna, Sneha, Muffly, Lori

“…Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22 + malignancies with progression after…”
Get full text

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study by Frank, Matthew J, Baird, John H, Kramer, Anne Marijn, Srinagesh, Hrishikesh K, Patel, Shabnum, Brown, Annie Kathleen, Oak, Jean S, Younes, Sheren F, Natkunam, Yasodha, Hamilton, Mark P, Su, Yi-Jiun, Agarwal, Neha, Chinnasamy, Harshini, Egeler, Emily, Mavroukakis, Sharon, Feldman, Steven A, Sahaf, Bita, Mackall, Crystal L, Muffly, Lori, Miklos, David B, Klysz, Dorota Danuta, Gkitsas-Long, Nikolaos, Bacigalupi, Juliana, Iglesias, Maria, Crawford, Emma, Nichols, Linnea, Cunanan, Kristen, Tamaresis, John, Spiegel, Jay Y., Ehlinger, Zachary, Kuo, Adam, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen Kai, Bharadwaj, Sushma, Dahiya, Saurabh, Smith, Melody, Schultz, Liora M., Ramakrishna, Sneha, Davis, Kara L., Tunuguntla, Ramya

“…Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a…”
Get full text

DIPG-47. SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS by Monje, Michelle, Mahdi, Jasia, Majzner, Robbie G, Yeom, Kristen, Schultz, Liora M, Richards, Rebecca, Barsan, Valentin, Song, Kun-Wei, Kamens, Jennifer, Baggott, Christina, Kunicki, Michael, Lim, Alexandria Sung, Reschke, Agnes, Mavroukakis, Sharon, Egeler, Emily, Moon, Jennifer, Patel, Shabnum, Chinnasamy, Harshini, Erickson, Courtney, Jacobs, Ashley, Duh, Allison K, Rietberg, Skyler P, Tunuguntla, Ramya, Klysz, Dorota Danuta, Fowler, Carley, Green, Sean, Beebe, Barbara, Carr, Casey, Fujimoto, Michelle, Brown, Annie Kathleen, Peterson, Ann-Louise G, McIntyre, Catherine, Siddiqui, Aman, Lepori-Bui, Nadia, Villar, Katlin, Pham, Kymhuynh, Bove, Rachel, Musa, Eric, Reynolds, Warren, Kuo, Adam, Prabhu, Snehit, Rasmussen, Lindsey, Cornell, Timothy T, Partap, Soni, Fisher, Paul G, Campen, Cynthia J, Grant, Gerald, Prolo, Laura, Ye, Xiaobu, Sahaf, Bita, Davis, Kara L, Feldman, Steven A, Ramakrishna, Sneha, Mackall, Crystal L

Get full text